* If you want to update the article please login/register
The preoperative evaluation of Parkinson's Disease patients for subthalamic nucleus deep brain stimulation involves the examination of the patient's neuropsychological status. The Montreal cognitive assessment has also been shown to be a quick, time-sparing instrument with high diagnostic reliability in PD. We investigate the Usability of the MoCA as a preoperative screening measure for PD patients undergoing bilateral STN-DBS. Patients receiving STN-DBS found significant postoperative cognitive decline in PD patients but not the MDRS. Patients with a MoCA score of 23 points had a dramatic decrease in quality of life after DBS surgery, relative to patients > 23 points. Conclusion: The MoCA has been identified as an alternative test in the preoperative evaluation of PD patients for the detection of neuropsychological abnormalities and prediction of postoperative quality of life.
Source link: https://doi.org/10.1371/journal.pone.0265314
Objective: Deep brain stimulation is a safe method of treating motor symptoms of advanced Parkinson's disease. Methods: Muscle activation measurements were performed in 13 patients with advanced PD and those treated with DBS. The measured EMG signals were analyzed with parameters that characterize the EMG signal morphology, and the results were compared to the adjustment's clinical outcome. The most significant signal recurrence rate was affected by the DBS adjustment, which raised the signal recurrence rate. Patients' Unified Parkinson's Disease Rating Scale motor part score dropped by 35% on average when compared to turning the device off. However, the changes in UPRDS-III arm tremor and rigidity scores did not differ significantly in any settings relative to the recommended stimulation conditions. Conclusion: DBS therapy adjustment changes the muscle activation patterns in PD patients.
Source link: https://doi.org/10.1371/journal.pone.0266936
Introduction: Impulse control disorders are common neuropsychiatric signs of Parkinson's disease. Impulsivity raises is a predictor of impulse control disorders and can therefore be managed. Methods: We conducted a prospective single-arm, open-label pilot trial to investigate the benefits of mindfulness meditation to reduce impulsivity in Parkinson's disease patients. Results: Twenty patients with Parkinson's disease were enrolled in an 8-week mindfulness meditation course. We investigated whether the Barratt Impulsiveness Scale's score had been significantly reduced after the intervention, as a primary result. Conclusions: This open-label, single-arm pilot study found preliminary results for mindfulness meditation to regulate patient impulsivity in patients with PD. A short mindfulness meditation course may be helpful in reducing impulsivity in PD and may alter the DMN's functional connectivity and right FPN.
Source link: https://doi.org/10.1371/journal.pone.0266354
Additionalcellular vesicles and Poly polymerase production, according to alpha synuclein-containing extracellular vesicles and Poly polymerase activity as primary PD pathogenesis and putative PD biomarkers. Methods: We collected plasma of 57 PD patients and compared it to 20 unaffected individuals, 20 people with clinically diagnosed Alzheimer's disease, and 20 individuals with dementia with Lewy bodies. PD patients were significantly higher in simulated vesicles than those in other groups. Patients with elevated -synuclein extracellular vesicles had a higher Unified Parkinson Disease Rating Scale score in the discovery study. Conclusions: The non-invasive determination of -synuclein-positive extracellular vesicles may be a non-invasive measure of PD disease severity, but longitudinal studies are required to determine the role of -synuclein-positive extracellular vesicles as a predictor of disease progression.
Source link: https://doi.org/10.1371/journal.pone.0264446
The aim of this study was to determine the reliability of the Parkinson's Disease Questionnaire-39 in PD patients with and without cognitive impairment. The PDQ-39's convergencent validity with the BDI decreased in the low MOCA group, but the PDQ-39 domain's total score and subdomain emotional well-being remained significant for the majority of PDQ-39 domains, particularly for the PDQ total score and subdomain emotional well-being. Conclusion: The PDQ-39 can be used to determine QoL in cognitively impaired PD patients, so test results indicating cognitive impairment alone should not lead to exclusion of PD patients from clinical trials. Although the relationship between BDI-III and PDQ-39 shrinks for some subdomains of cognitively impairment patients, this finding may be explained by the different in PD severity as factors influencing QoL change with increasing age and PD symptoms.
Source link: https://doi.org/10.1371/journal.pone.0266140
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions